Rheumatoid arthritis and incidence of twelve initial presentations of cardiovascular disease: a population record-linkage cohort study in England by Pujades Rodriguez, M et al.
RESEARCH ARTICLE
Rheumatoid Arthritis and Incidence of
Twelve Initial Presentations of Cardiovascular
Disease: A Population Record-Linkage Cohort
Study in England
Mar Pujades-Rodriguez1,2*, Bram Duyx1, Sara L. Thomas3, Dimitris Stogiannis1,
Anisur Rahman4, Liam Smeeth1,3, Harry Hemingway1
1 Farr Institute of Health Informatics Research, University College London, 222 Euston Road, London NW1
2DA, United Kingdom, 2 Leeds Institute of Biomedical and Clinical Sciences, MRCMedical Bioinformatics
Centre, Worsley Building, University of Leeds, Leeds LS2 9JT, United Kingdom, 3 Department of Non-
communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street,
LondonWC1E 7HT, United Kingdom, 4 Centre of Rheumatology Research, Division of Medicine, Faculty of
Medical Sciences, University College London, LondonWC1E 6JF, United Kingdom
*M.D.M.PujadesRodriguez@leeds.ac.uk
Abstract
Introduction
While rheumatoid arthritis is an established risk factor for cardiovascular disease (CVD),
our knowledge of how the pattern of risk varies for different cardiovascular phenotypes is
incomplete. The association between rheumatoid arthritis and the initial presentation of
12 types of CVDs were examined in a contemporary population of men and women of a
wide age range.
Methods
CALIBER data, which links primary care, hospital and mortality data in England, was ana-
lysed. A cohort of people aged18 years and without history of CVD was assembled and
included all patients with prospectively recorded rheumatoid arthritis from January 1997,
until March 2010, matched with up to ten people without rheumatoid arthritis by age, sex
and general practice. The associations between rheumatoid arthritis and the initial presen-
tation of 12 types of CVDs were estimated using multivariable random effects Poisson
regression models.
Results
The analysis included 12,120 individuals with rheumatoid arthritis and 121,191 compara-
tors. Of these, 2,525 patients with and 18,146 without rheumatoid arthritis developed CVDs
during a median of 4.2 years of follow-up. Patients with rheumatoid arthritis had higher rates
of myocardial infarction (adjusted incidence ratio [IRR] = 1.43, 95%CI 1.21–1.70), unher-
alded coronary death (IRR = 1.60, 95%CI 1.18–2.18), heart failure (IRR = 1.61, 95%CI
1.43–1.83), cardiac arrest (HR = 2.26, 95%CI 1.69–3.02) and peripheral arterial disease
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(HR = 1.36, 95%CI 1.14–1.62); and lower rates of stable angina (HR = 0.83, 95%CI 0.73–
0.95). There was no evidence of association with cerebrovascular diseases, abdominal aor-
tic aneurysm or unstable angina, or of interactions with sex or age.
Conclusions
The observed associations with some but not all types of CVDs inform both clinical practice
and the selection of cardiovascular endpoints for trials and for the development of prognos-
tic models for patients with rheumatoid arthritis.
Introduction
Studies have reported a 1.5 to 2-fold increase in risk of acute myocardial infarction (AMI),
cerebrovascular disease[1–5] or cardiovascular mortality[6–8] in people with rheumatoid
arthritis (RA). The absolute cardiovascular risk in individuals with this chronic inflammatory
condition has been estimated to be similar to that in non-RA individuals who are approxi-
mately ten years older[9], and research suggests that the risk is similar to that seen in people
with type 2 diabetes[10–12]. Both traditional risk factors and underlying disease may contrib-
ute to the increased cardiovascular risk[13]. Possible mechanisms include chronic immune
dysregulation and systemic inflammation[14,15], induction of cardiovascular risk factors by
medication (e.g. some disease-modifying antirheumatic drugs [DMARDs], oral corticosteroids
or non-steroidal anti-inflammatory drugs), or common risk factors for RA and cardiovascular
disease (CVD) such as genes[16] or smoking[17,18].
Previous studies have included only a limited range of cardiovascular endpoints, generally
AMI and all-cause stroke, and most have been small or were undertaken prior to the wide-
spread use of modern therapies for RA and to the introduction of an earlier and more aggres-
sive pharmacological management[19].
The availability of linked electronic health records from primary care, hospital, disease reg-
istries and mortality through CALIBER (CArdiovascular research using LInked Bespoke stud-
ies and Electronic health Records)[20–23], offers the opportunity to investigate the association
between RA and the initial presentation of specific types of CVDs in a contemporary popula-
tion in England. The validity of both risk factor and disease measurements in CALIBER is sup-
ported by findings replicating and extending anticipated associations between phenotypic
definitions for the 12 most common symptomatic CVDs and smoking[21], systolic and dia-
stolic blood pressure[23], diabetes[24], and socio-economic deprivation[22].
The objectives of this analysis were to compare the rates of specific types of CVDs in indi-
viduals with and without RA and no prior history of CVD; and to investigate whether associa-
tions differ according to disease duration, sex, age, or presence of other autoimmune diseases
in a contemporary population.
Methods
Study Population
All patients with a recorded RA diagnosis among individuals registered in the general practices
contributing data to CALIBER between January 1997 and March 2010 were included. For each
of these, up to ten individuals matched on age (±5 years), sex and general practice were ran-
domly selected amongst those not diagnosed with the disease on their matched inclusion date
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(concurrent sampling), who were alive and actively registered in the same practice (i.e. with a
practice contact record within 1 year of the inclusion date to ensure that they had the same
opportunity for clinical diagnosis and reporting of risk factors and outcomes). Inclusion crite-
ria were age18 years, no history of CVD and contributing at least one year of data after regis-
tering with the practice. Patients with juvenile RA, and those with no RA diagnosis but with
prescribed DMARD or biologic therapy suggestive of RA disease were excluded from the non-
RA group (Figure A in S1 File). Patient electronic medical records linked across four data
sources were analysed: the Clinical Practice Research Datalink (CPRD)[25]; the Myocardial
Ischaemia National Audit Project disease registry[26]; Hospital Episodes Statistics (HES); and
the national death registry.
Rheumatoid arthritis
Patients with RA were identified from electronic medical records in CPRD and HES using
Read and International Classification of Disease (ICD) version 10 codes, respectively (Table A
in S1 File). The validity of Read codes of RA has been demonstrated in studies conducted in
this and similar medical databases[27,28]. Individuals with RA who additionally had support-
ing information for diagnosis (at least one diagnosis code for RA in both primary [CPRD] and
secondary [HES] care, a DMARD or biologic therapy prescription [Table B in S1 File], or a
visit to rheumatology clinic within 6 months of the diagnosis code; or a positive rheumatoid
factor test or anti-cyclic citrullinated peptide antibody test after diagnosis), were included in
primary analyses regardless of disease duration. Patients with no supporting information for
diagnosis were also included in sensitivity analyses. For secondary analyses, individuals were
classified into incident and prevalent RA cases, depending on whether diagnosis was made
before or after the start of the observation period (‘index date’).
Baseline covariates
Baseline covariates considered in the analysis were: sex, age, index of multiple deprivation[22],
diagnosed diabetes mellitus[24], smoking status[21], body mass index (BMI), systolic blood
pressure, medication use (2 prescriptions of nonsteroidal anti-inflammatory drugs, oral cor-
ticosteroids, blood pressure lowering drugs and statins), year of study start and other diagnosed
autoimmune diseases (Table C in S1 File). The most recent measurement of quantitative vari-
ables such as blood pressure (or prescription for medication) recorded in CPRD up to one year
before study entry was used to define baseline covariates. The index of multiple deprivation is a
composite indicator that provides a relative ranking of areas across the United Kingdom
according to seven domains of deprivation: i) income; ii) employment; iii) health and disability;
iv) education, skills and training; v) barriers to housing and services; vi) crime; and vii) living
environment[29]. Patients with coded diagnoses of diabetes (type 1, type 2 or uncertain type)
recorded in CPRD or HES at or before study entry were considered to have diabetes at baseline.
Definitions can be found at https://www.caliberresearch.org/portal/.
Endpoints
The primary endpoints for the analysis were the initial presentation of fatal and non-fatal
CVDs. CVD presentations studied were: i) cardiac diseases: stable angina, unstable angina,
AMI, heart failure, cardiac arrest; ii) cerebrovascular diseases: transient ischaemic attack,
ischaemic stroke, subarachnoid haemorrhage, intracerebral haemorrhage; and iii) peripheral
vascular diseases: PAD, and abdominal aortic aneurysm. Secondary endpoints were two com-
posite CVD outcomes defined as for the estimation of the 1998 and 2008 Framingham predic-
tion scores, the coronary and CVD death composite (including stable angina, AMI, coronary
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heart diseases not otherwise specified, and any CVD death), and the fatal and non-fatal cardio-
vascular composite (additionally including non-fatal heart failure, transient ischaemic attack,
ischaemic or haemorrhagic stroke, and PAD); and the first event of each CVD type (i.e. regard-
less of other earlier CVD presentations). Diagnosis codes used to define each endpoint can be
found at http://www.caliberresearch.org/portal/.
Study follow-up period
For individuals with RA the observation period began on the date when the patient fulfilled all
the study inclusion criteria, or the date of first recorded diagnosis code for RA. For non-RA
patients, the observation period started on the index date of the matched RA individual. The
observation period for all patients ended on the date of cardiovascular endpoint diagnosis,
death unrelated to the study endpoints, practice deregistration, last date of data collection in
the practice, or diagnosis of RA (for patients who contributed follow-up to both the rheuma-
toid and non-rheumatoid disease groups).
Statistical analysis
Incidence rates of events per 1000 person-years of follow-up with 95% confidence intervals
were calculated in patients with and without RA, and separately for patients with prevalent or
incident disease. To examine associations between disease and each study endpoint we used
random-effects Poisson regression models accounting for clustering between practices. The
strategy for adjustment was defined a priori. Models were initially adjusted for the confounding
effects of age and sex, then additionally for established cardiovascular risk factors (multiple
deprivation, diabetes mellitus, smoking status, BMI, and systolic blood pressure). Missing val-
ues of smoking status, systolic blood pressure, and BMI were multiply imputed (Multiple
imputation in S1 File). Systolic blood pressure and BMI were incorporated into the models as
continuous variables. Age as linear and quadratic terms. To explore possible pathways or medi-
ators of any increase in risk, estimates were further adjusted for: i) lipid and blood pressure
lowering medication, ii) diagnosis of another autoimmune disease, iii) anti-inflammatory
drugs (nonsteroidal, and oral corticosteroid medication); and iv) calendar year of inclusion.
Heterogeneity in associations across CVD endpoints was assessed with the I-squared[30],
assuming independence in effects.
In secondary analyses, interactions with age and sex were investigated as well as associations
with prevalent and incident RA. Furthermore, to assess the association between disease dura-
tion and CVD, we used time-dependent covariates. For this, we split the follow-up of individu-
als with incident RA into periods of disease duration (0–1, 2–4, 5–9 and10 years) and only
included individuals with prevalent RA who had their first recorded diagnosis 10 years or more
before study entry (categorised in the10 year duration period). Individuals with prevalent
disease but shorter disease duration were excluded from this secondary analysis because of
uncertainty about the time since diagnosis. In addition, because previous studies suggested that
the risk of CVD is similar to that seen in people with type 2 diabetes[10–12], we compared esti-
mates for the two diseases examining the overlap of confidence intervals.
Sensitivity analyses comprised: i) exclusion of individuals with another autoimmune dis-
ease; ii) restriction to individuals with at least 6 months of patient-time follow-up; and iii)
exclusion of 2 years of follow-up prior to the diagnosis of RA for individuals who contributed
to the disease and unexposed groups; iv) inclusion of individuals without supporting informa-
tion for RA diagnosis (one data source); v) inclusion of first cardiovascular events irrespective
of other earlier CVD presentations; and vi) comparison of estimates in the periods before and
after the introduction of the pay for performance scheme in England (Quality of Outcomes
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Framework). This scheme financially rewards general practices for meeting a range of quality
targets in several areas, including the improvement of management of chronic diseases and
how practices are organised.
Analyses were performed using Stata v13.1 (StataCorp LP).
Approval was granted by the Independent Scientific Advisory Committee of the Medicines
and Healthcare Products Regulatory Agency and the Myocardial Ischaemia National Audit
Project Academic Group. The protocol was registered at clinicaltrials.gov (NCT02062021).
Data was anonymised and de-identified prior to analysis.
Results
Patient characteristics
In total 12,120 individuals with RA and supporting diagnostic information (Fig 1), and 121,191
matched non-RA individuals with no prior history of CVD were included in the primary analy-
ses. Of these, 736 individuals contributed follow-up time to both the RA and non-RA groups.
Fifty percent of individuals with RA (n = 6,095) had incident disease and 56.7% of those with
prevalent disease had been diagnosed 5 years or more before study entry. Overall, median
duration of registration in the practice was 10.7 years (IQR 4.5–20.4). Median age at study
entry was 57 years [IQR 46–67] and 72.3% were women (Table 1). Individuals included in the
study contributed 675,489 person-years of follow-up, with a median of 4.2 years. Of patients
with RA, 54.0% received nonsteroidal anti-inflammatory drugs, 22.1% corticosteroids and
Fig 1. Study flow diagram.Note: CVD, cardiovascular disease; RA, rheumatoid arthritis; SID, supportive information for rheumatoid arthritis diagnosis.
doi:10.1371/journal.pone.0151245.g001
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50.9% DMARDs or biologic therapy (69.0% of prevalent and 33.1% of incident rheumatoid dis-
ease patients) in the year before study entry. Eighty-three percent of individuals with RA had at
least one recorded prescription of DMARDs or biologic therapy within 6 months of a diagnosis
code. Diagnosis with another autoimmune disease was recorded in 16.1% of RA patients and
5.2% of non-RA patients. The distribution of traditional cardiovascular risk factors was similar
among individuals with and without RA except for the higher prevalence of current or former
smoking among patients with RA (41.9% vs. 33.4%). At baseline 3,835 (31.6%) patients with
RA and 4,089 non-RA patients had results of rheumatoid factor testing recorded; a positive test
was found in 45.8% and 6.5% of these patients, respectively.
Table 1. Characteristics* of individuals with and without rheumatoid arthritis.
Patients without RA All patients with RA
N = 121,191 N = 12,120
Sociodemographic factors
Age in years, median [IQR] 56 [45–67] 59 [48–68]
Women, n (%) 87,640 (72.3) 8764 (72.3)
Index of multiple deprivation in quintiles, n (%)
1 (most deprived) 24,770 (20.5) 2329 (19.3)
5 (least deprived) 23,855 (19.8) 2627 (21.8)
Ethnicity, n (%)
White 66,789 (94.8) 8722 (95.0)
Asian 1539 (2.2) 264 (2.9)
Afro-Caribbean 1188 (1.7) 102 (1.1)
Other 930 (1.3) 90 (1.0)
Duration of registration in years, median [IQR] 10.7 [4.6–20.4] 11.0 [3.9–20.9]
Consultation rate in previous year 4 [2–8] 9 [5–15]
Cardiovascular risk factors
Smoking, n (%)
Current 11,276 (12.7) 1443 (16.2)
Former 18,343 (20.7) 2287 (25.7)
Never 58,919 (66.6) 5186 (58.2)
Diabetes 4955 (4.1) 558 (4.6)
Systolic blood pressure in mmHg, mean (SD) 135 (19.6) 136 (19.5)
Body mass index in kg/m2, mean (SD) 26.8 (5.4) 26.7 (5.7)
Total cholesterol in mmol/L, mean (SD) 5.6 (1.1) 5.4 (1.1)
HDL cholesterol in mmol/L, mean (SD) 1.5 (0.4) 1.4 (0.5)
Other autoimmune disease diagnosed, n (%) 6275 (5.2) 1959 (16.1)
Medication use in previous year
DMARDs and biologic therapy, n (%) 125 (0.1) 6172 (50.9)
Nonsteroidal anti-inﬂammatory drugs, n (%) 10,759 (8.9) 6547 (54.0)
Oral corticosteroids, n (%) 2022 (1.7) 2678 (22.1)
Blood pressure lowering medication, n (%) 27,248 (22.5) 3199 (26.4)
Statins, n (%) 6200 (5.1) 603 (5.0)
Note: DMARDs, disease-modifying anti-rheumatic drugs; HDL, high-density lipoprotein; IQR, interquartile range; RA, rheumatoid arthritis; SD, standard
deviation. All patients with rheumatoid arthritis (regardless of disease duration) are included.
*Missing data (%): index of multiple deprivation, 0.3%; ethnic group, 40.3%; BMI, 39.0%; systolic blood pressure, 17.7%; smoking, 26.9%; total
cholesterol, 70.7%; HDL cholesterol, 90.5%.
doi:10.1371/journal.pone.0151245.t001
Rheumatoid Arthritis and Incidence of Twelve Cardiovascular Diseases
PLOS ONE | DOI:10.1371/journal.pone.0151245 March 15, 2016 6 / 15
Association between rheumatoid arthritis and 12 CVDs
During follow-up, 2,525 (20.8%) RA and 18,146 (15.0%) non-RA individuals experienced a
cardiovascular event. The incidence of CVD was higher in patients with RA, 35.33/1000 per-
son-years (95%CI 33.91–36.80) compared with 27.20/1000 person-years (95%CI 26.79–27.62)
in non-RA patients for the fatal and non-fatal CVD composite endpoint (Table 2). Individuals
Table 2. Incidence of the initial presentation of twelve cardiovascular diseases with 95% confidence interval in individuals with and without rheu-
matoid arthritis.
Patients without RA
(N = 121,191)
All patients with RA
(N = 12,120)
Patients with prevalent RA
(N = 6025)
Patients with incident RA
(N = 6095)
No. of
events
Rate / 1000 PY
(95% CI)
No. of
events
Rate / 1000 PY
(95% CI)
No. of
events
Rate / 1000 PY
(95% CI)
No. of
events
Rate / 1000 PY
(95% CI)
Cardiac diseases
Stable angina 3455 5.66 (5.48–
5.85)
341 5.22 (4.69–
5.80)
204 5.55 (4.83–
6.36)
137 4.79 (5.48–
5.85)
Unstable angina 782 1.28 (1.19–
1.37)
89 1.36 (1.11–
1.68)
61 1.66 (1.29–
1.13)
28 0.98 (0.68–
1.42)
Myocardial infarction 1778 2.91 (2.78–
3.05)
301 4.61 (4.11–
5.16)
203 5.52 (4.81–
6.33)
98 3.43 (2.81–
4.18)
Unheralded coronary
death
887 1.45 (1.36–
1.55)
130 1.99 (1.67–
2.36)
89 2.42 (1.97–
2.98)
41 1.43 (1.06–
1.95)
Cardiac arrest 343 0.56 (0.51–
0.62)
73 1.12 (0.89–
1.40)
46 1.25 (0.94–
1.67)
27 0.94 (0.65–
1.38)
Heart failure 3006 4.93 (4.75–
5.11)
533 8.15 (7.49–
8.88)
351 9.54 (8.59–
10.59)
182 6.37 (5.51–
7.37)
Cerebrovascular
diseases
Transient ischaemic
attack
1489 2.44 (2.32–
2.57)
159 2.43 (2.08–
2.84)
98 2.66 (2.19–
3.25)
61 2.13 (1.66–
2.74)
Ischaemic stroke 885 1.45 (1.36–
1.55)
110 1.68 (1.40–
2.03)
71 1.93 (1.53–
2.44)
39 1.36 (1.00–
1.87)
Subarachnoid
haemorrhage
163 0.27 (0.23–
0.31)
24 0.37 (0.25–
0.55)
15 0.41 (0.25–
0.68)
9 0.31 (0.16–
0.61)
Intracerebral
haemorrhage
274 0.45 (0.40–
0.51)
37 0.57 (0.41–
0.78)
23 0.63 (0.42–
0.94)
14 0.49 (0.29–
0.83)
Peripheral vascular
diseases
Peripheral arterial
disease
1569 2.57 (2.45–
2.70)
264 4.04 (3.58–
4.56)
171 4.65 (4.00–
5.40)
93 3.25 (2.66–
3.99)
Abdominal aortic
aneurysm
395 0.65 (0.59–
0.71)
53 0.81 (0.62–
1.06)
38 1.03 (0.75–
1.42)
15 0.52 (0.32–
0.87)
CVD composite
endpoints
Coronary & CVD death 8312 13.62 (13.33–
13.92)
1030 15.76 (14.83–
16.75)
659 17.91 (16.60–
19.34)
371 12.98 (11.73–
14.37)
Fatal and non-fatal 16,596 27.20 (26.79–
27.62)
2309 35.33 (33.91–
36.80)
1501 40.80 (38.79–
42.92)
808 28.28 (26.39–
30.30)
Note: CI, conﬁdence interval; CVD, cardiovascular disease; Non-rheumatoid arthritis estimates are obtained among up to 10 randomly selected patients
with no rheumatoid arthritis matched for sex, age, medical practice and index date; PY, person-years of follow-up; RA, rheumatoid arthritis. Rates are
unadjusted; Rheumatoid arthritis estimates are obtained among all patients diagnosed with rheumatoid arthritis (regardless of disease duration) who had
supporting information for disease diagnosis. The coronary and CVD death composite endpoint includes: stable angina, myocardial infarction, coronary
heart diseases not otherwise speciﬁed and any cardiovascular death. The fatal and non-fatal CVD composite endpoint additionally includes: non-fatal
heart failure, transient ischemic attack, ischemic or haemorrhagic stroke, and peripheral arterial disease.
doi:10.1371/journal.pone.0151245.t002
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with RA had increased incidence rates of AMI, unheralded coronary death, heart failure, car-
diac arrest and PAD; and lower rates of stable angina (Fig 2). No evidence of a relationship was
found for unstable angina, transient ischaemic attack, ischaemic or haemorrhagic stroke or
abdominal aortic aneurysm. Associations were heterogeneous across cardiovascular endpoints
(I2 = 89.8, p<0.0001). Further adjustment for the presence of other autoimmune diseases and
for prescribed CVD and anti-inflammatory medication in the previous year had no effect or
tended to decrease the size of associations. Controlling for the effect of specific types of anti-
inflammatory drugs generally showed greater reductions in rate ratios for oral corticosteroid
use (Figure B in S1 File). However further adjustment for year of entry did not change the esti-
mates (Figure C in S1 File). No evidence of effect modification by sex or age was found for any
of the endpoints (Figures D and E in S1 File).
Higher incidence ratios were generally observed for individuals with prevalent than with
incident rheumatoid disease compared to those without RA (Fig 3), with stronger evidence for
a difference for AMI and PAD. Except for unheralded coronary death, rates of specific CVDs
were higher in individuals with recently diagnosed RA (<1 year) than in those with RA disease
duration of 2–9 years, but no difference was seen between patients with the shortest (<1 year)
and longest (10 years) disease duration periods (Figure F in S1 File). In contrast to patients
with RA, those with diabetes had also increased rate ratios of stable and unstable angina,
Fig 2. Adjusted incidence rate ratios for the association between rheumatoid arthritis and the initial presentation of twelve cardiovascular
diseases. [Fig note: CI, confidence interval; CVD, cardiovascular disease; IRR, incidence rate ratios; n, number of events. CVD risk factors included index of
multiple deprivation, smoking status, systolic blood pressure, body mass index and diabetes. All patients with rheumatoid arthritis (regardless of disease
duration) are included. Because of the limited number of events, estimates for cardiac arrest, subarachnoid haemorrhage, intracerebral haemorrhage and
abdominal aortic aneurysm are adjusted for sex, age, index of multiple deprivation, smoking and diabetes. CVDmedications included use of blood pressure
and lipid lowering medication. Anti-inflammatory medication included nonsteroidal anti-inflammatory drugs and oral corticosteroids.]
doi:10.1371/journal.pone.0151245.g002
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ischaemic stroke and intracerebral haemorrhage, but not increased ratios of cardiac arrest
(Figure G in S1 File). For statistically significant associations, the size of the estimates was com-
parable to those of diabetes except for the higher ratios found among diabetic patients (vs.
non-diabetic individuals) for stable angina and PAD.
Results from sensitivity analyses
Estimates of association were robust to sensitivity analyses that excluded individuals diagnosed
with another autoimmune disease, excluded individuals with 6 months or more of study fol-
low-up, and censored follow-up two years before the diagnosis of RA in individuals who con-
tributed with study follow-up to both, diseased and non-diseased exposure groups (Table D
and Figure H in S1 File). Similarly, associations did not differ when they were compared in the
periods before and after the introduction of the pay for performance system in England (April
2004; Figure I in S1 File) or when patients without supporting information for RA diagnosis
were also included (Figure J in S1 File). Patterns of associations remained unchanged when
first occurrence of CVD was studied regardless of prior presentation with other type of CVD
(Figure K in S1 File).
Discussion
In this comprehensive and contemporary evaluation of the burden of CVDs associated with
RA, we reported between thirty-six percent and two-fold higher rates of AMI, unheralded cor-
onary death, heart failure, cardiac arrest and PAD in individuals diagnosed with the disease;
but lack of association with unstable angina, cerebrovascular diseases or abdominal aortic
aneurysm. Increased rates were found in both individuals with incident and prevalent RA, esti-
mates’ size generally being similar to those observed in diabetic patients. Among individuals
with incident RA, the highest CVD rates during follow-up were observed during the first year
and after ten years of RA diagnosis. Rates were similar in men and women and findings were
robust to multiple sensitivity analyses.
Fig 3. Adjusted incidence rate ratios of the initial presentation of twelve cardiovascular diseases for incident and prevalent rheumatoid arthritis
(vs. non-rheumatoid arthritis). [Figure note: CI, confidence interval; IRR, incidence rate ratios adjusted for sex, age, index of multiple deprivation, smoking
status, systolic blood pressure, body mass index and diabetes (or rheumatoid arthritis). Because of the limited number of events, estimates for cardiac arrest
are not adjusted for body mass index; and estimates for subarachnoid haemorrhage, intracerebral haemorrhage and abdominal aortic aneurysm are
adjusted for sex, age, index of multiple deprivation, smoking and diabetes (or rheumatoid arthritis).]
doi:10.1371/journal.pone.0151245.g003
Rheumatoid Arthritis and Incidence of Twelve Cardiovascular Diseases
PLOS ONE | DOI:10.1371/journal.pone.0151245 March 15, 2016 9 / 15
The strengths of this analysis are the population-based design of broad age span (18–99
years), large sample size (N = 133,311 in the main analysis), a cohort including all ranges of RA
severity and information from individuals treated in recent years (1997–2010), and the study
of the twelve most common clinical presentations of CVDs. Previous studies assessed only a
limited range of cardiovascular endpoints, generally myocardial infarction and all-cause stroke,
and most were small or were undertaken prior to the widespread use of modern therapies for
rheumatoid arthritis and to the introduction of an earlier (i.e. within 3 months of onset) and
more aggressive pharmacological management of patients with a combination of DMARDs
and with short-courses of glucocorticoids for the management of flares. The cohort design and
the unique data source linking EHRs covering primary care, hospital and mortality data
allowed identification of a non-RA group selected from the same population and improved
ascertainment of cardiovascular outcomes, which have been found to be valid[31,32] and were
determined independently of RA status. Unlike previous studies, we were able to study not
only the effect of adjusting for the presence of established cardiovascular risk factors but also
for prescribed anti-inflammatory and cardiovascular medication currently used in clinical
practice and for the presence of other diagnosed autoimmune diseases. We were also able to
investigate in the same study differences in associations between patients with prevalent and
incident RA, and according to RA disease duration, providing the most comprehensive picture
of the burden of CVDs related to RA published to date.
One of the limitations of the study, inherent to the use of EHRs, was the possibility of RA
diagnosis misclassification (e.g. mild or atypical RA patients might be less likely to be diag-
nosed and some diagnoses made in primary care could be inaccurate). However, we used the
same diagnosis codes previously validated within the same or analogous medical databases and
for which positive predictive values between 74% and 81% have been reported[27,28], and the
primary analysis included only RA patients with supporting information for diagnosis. Typical
DMARDmedication or record of multiple diagnosis codes in primary care have been shown to
increase the validity of RA diagnosis by general practitioners (80% sensitivity and specificity)
[33]. Furthermore, although changes in clinical diagnosis and management over time could
affect the estimates, ensuring that non-disease matched individuals were registered in the same
practices at study inclusion minimised the introduction of this type of bias. Model adjustment
for calendar-year had also negligible effects on the estimates (Figure C in S1 File).
In the cohort analysed the distribution of established cardiovascular risk factors was similar
in individuals with or without RA, except for the higher prevalence of current or former smok-
ing among RA patients. Smoking has been identified as a risk factor for the development of RA
in previous studies[17] and for high antibody titres of rheumatoid factor and anti-citrullinated
protein[18]. In our analysis, adjustment for the effect of smoking and other cardiovascular risk
factors measured at baseline decreased the size of the estimates but did not completely explain
the observed increased risk of CVDs in RA patients. However, residual confounding resulting
from lack of information on known (e.g. rheumatoid factor status or lipids) or unknown risk
factors cannot be completely excluded. Furthermore, precise information about time of diagno-
sis and the duration of and compliance with medication was not available and changes in medi-
cation use over time associated with RA flares were not investigated. The effect of anti-
inflammatory drugs on CVD is complex. While reductions of cardiovascular risk could be
mediated through their anti-inflammatory properties, they could also facilitate progression of
atherosclerosis (e.g. corticosteroid could increase cardiovascular risk through effects on blood
pressure, lipid profile and insulin resistance[34]). Indeed a meta-analysis of 280 trials of non-
steroidal anti-inflammatory drugs showed increased risk of coronary heart disease and death
and heart failure associated with coxibs, diclofenac or ibuprofen use[35]. Alternatively, because
oral corticosteroids and nonsteroidal anti-inflammatory drugs are generally prescribed when
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substantial joint inflammation is present, adjusting for anti-inflammatory medication could
result in estimate underestimation. In our study, additionally adjusting for baseline prescrip-
tion of anti-inflammatory medication further decreased the magnitude of the estimates but
associations with myocardial infarction, heart failure and cardiac arrest remained statistically
significant.
The duration of follow-up was limited, with a median time of four years per patient, but
2,125 patients with incident RA contributed with ten years or more of study follow-up to the
analysis. The increased risk of CVD was observed at both, early stages of the disease and ten
years or more after disease diagnosis, and in both patients with incident and prevalent disease.
Results were robust to exclusion of patients who received oral corticosteroids and DMARDs or
biologic therapy in the year before study entry. Although it is debated whether the timing of
increase in risk of CVD is before or soon after the clinical onset of RA[18], our findings are
consistent with smaller longitudinal studies reporting higher risk of coronary heart disease
[36,37] and congestive heart failure[38] early after disease diagnosis. Our results suggest that
the mechanism by which RA increases the cardiovascular risk is not exclusively related to a
cumulative inflammatory burden but to other shared pathogenic mechanisms between the two
types of disease[38].
The observed associations are consistent with results from meta-analyses that reported
increased risk of fatal[6] and non-fatal[39] AMI, absence of relationship with stroke[3] and of
sex-differences in these associations[39]. The lower risk of stable angina and the increased risk
of initial presentation of CVD with unheralded coronary death in patients with RA are of clini-
cal relevance and consistent with reports of a higher risk of undiagnosed mild vascular disease
and unrecognised AMI and sudden cardiac death[40] in RA patients who suffer from chronic
pain and frequently use analgesic drugs[18,40]. Although other less common mechanisms can-
not be excluded (e.g. sensory disorders associated with neurological complications), these find-
ings suggest that some deaths could be averted if patients are adequately informed of the high
risk of unrecognised coronary disease and educated on how to recognise the symptoms. In our
study, we did not find evidence of association between RA status and different types of cerebro-
vascular diseases, including ischaemic and haemorrhagic stroke. Evidence of the association
between stroke and RA is conflicting and while a review reported increased risk of AMI but not
stroke3, several meta-analyses found increased risk of both fatal and non-fatal endpoints
[4,6,39]. Because higher risk of stroke was often reported in large studies and inception cohorts
usually failed to find evidence of association, suggested reasons for discrepancies have been a
shorter duration of RA disease and/or follow-up, less disease severity, differences in clinical
management of patients (i.e. more aggressive in recent years) or age distributions in RA popu-
lations, lack of power, or absence of adjustment for the effect of cardiovascular risk factors. The
numbers of events for some of the subtypes of stroke limited the power of some of the analyses
but, in contrast to estimations for diabetes, we did not find evidence of association not only
between RA (all RA patients, or patients with prevalent or incident RA) and specific types of
stroke but also with a composite endpoint of all types of stroke investigated (data not shown)
in a population with no prior history of CVD. Future analyses in larger populations and/or
when longer follow-up data will be available will help to understand better the reasons for the
observed lack of association with cerebrovascular endpoints.
The magnitude of cardiovascular risk estimates (similar to diabetes for several CVDs) has
implications for clinical practice and supports the incorporation of regular determination and
monitoring of cardiovascular risk early after RA diagnosis. While current ERC[41] and
EULAR[42] guidelines recognise the importance of adequate clinical management of patients
with RA to prevent CVDs, the equivalent USA guidelines, including new ACC/AHA recom-
mendations[43], do not mention the need for cardiovascular assessment and management.
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Furthermore, although no intervention studies have been conducted to evaluate the effective-
ness of implementing primary prevention therapy and monitoring of targets for RA patients,
the study findings support the need for this type of research. Likewise, evidence of the associa-
tion between RA and subsequent development of specific cardiovascular conditions other than
AMI (e.g. heart failure and cardiac arrest) but a lack of relationship with others (e.g. cerebro-
vascular disease) in the general population has important implications for risk prediction,
given that current recommended risk scores for patients with RA have been developed using
angina, AMI and cerebrovascular endpoints[44].
In conclusion, regardless of the mechanisms for the observed associations with some but
not all types of CVDs, our findings are important to inform both clinical practice and the
choice of cardiovascular endpoints for risk prediction model development and trials targeted at
patients with RA.
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